MicroRNA‐1 overexpression increases chemosensitivity of non‐small cell lung cancer cells by inhibiting autophagy related 3‐mediated autophagy
Sign Up to like & getrecommendations! Published in 2018 at "Cell Biology International"
DOI: 10.1002/cbin.10995
Abstract: Non‐small cell lung cancer (NSCLC) is a major type of lung cancer. Drug resistance is a enormous obstacle for cancer treatment. Copious microRNAs (miRNAs) have been demonstrated to be implicated in drug resistance in NSCLC.… read more here.
Keywords: overexpression; nsclc cells; ddp resistant; cancer ... See more keywords
TIPE2 suppressed cisplatin resistance by inducing autophagy via mTOR signalling pathway.
Sign Up to like & getrecommendations! Published in 2020 at "Experimental and molecular pathology"
DOI: 10.1016/j.yexmp.2020.104367
Abstract: Tumour necrosis factor-α-induced protein-8-like-2 (TIPE2) has been associated with the progression of numerous cancers. Cisplatin, as a classical chemotherapy strategy for cancers, has been applied in non-small-cell lung cancer (NSCLC) clinical therapy but bears the… read more here.
Keywords: tipe2; cisplatin; mtor; cisplatin resistance ... See more keywords
Abstract 1571: The feasibility and pharmacological mechanism of cucurbitacin E for the treatment of EGFR-TKI-primary resistant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1571
Abstract: Lung cancer ranks the leading cause of cancer death, with an estimated 1.8 million deaths according to the latest global cancer statistics. In the United States, there will be an estimated 236,740 new cases diagnosed,… read more here.
Keywords: resistant nsclc; treatment; egfr; primary resistant ... See more keywords
Apatinib for EGFR-TKIs resistant NSCLC patients: Initial clinical experience.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14059
Abstract: e14059Background: The 3rd generation TKI is still not available for Chinese NSCLC patients with EGFR-mutant who develop acquired resistance following treatment with 1st EGFR tyrosine kinase inhibit... read more here.
Keywords: apatinib egfr; egfr tkis; nsclc patients; tkis resistant ... See more keywords